Back to News
Market Impact: 0.35
Atom Therapeutics to Present Phase 2b/3 Data Showing Superior Efficacy of Lingdolinurad (ABP-671), Compared to Febuxostat, for Patients with Chronic Gout and Hyperuricemia at ACR Convergence 2026
Source: Business Wire
Healthcare & Biotech
Phase 2b/3 trial results reported that lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia. The article excerpt provides no efficacy figures, safety results, or further details on the trial.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Vertex Pharma meets Q3 estimates, raises revenue guidance